SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
biogen
biogen
Page 3 of 4
Newsletters
Biogen is doubling down on Alzheimer’s with a massive gene therapy deal
By
Sy Mukherjee
February 28, 2020
Leadership
Biogen CEO on Controversial Alzheimer’s Drug: ‘There Is Hope’
By
Susie Gharib
December 6, 2019
Newsletters
The Broader Implications of Biogen’s Divisive Alzheimer’s Drug
By
Sy Mukherjee
December 5, 2019
Newsletters
Biogen Stock Falls After Analyst Throws Cold Water on Its Alzheimer’s Drug Bet
By
Sy Mukherjee
December 2, 2019
Newsletters
Let’s Talk About Biogen’s Stunning Alzheimer’s Drug Reversal: Brainstorm Health
By
Sy Mukherjee
October 23, 2019
Biogen Acquires Nightstar Therapeutics in $800 Million Gene Therapy Deal
By
Don Reisinger
March 4, 2019
Health
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
By
Clifton Leaf
July 30, 2018
Health
Biogen’s Stock Is Soaring Because of Its Experimental Alzheimer’s Drug — But Some Are Urging Caution
By
Sy Mukherjee
July 6, 2018
Health
Alzheimer’s Cases Are Expected to Double By 2060 and We’re Not Ready for It
By
Sy Mukherjee
December 7, 2017
Health
We’ve Had Terrible Luck Trying to Cure Alzheimer’s. But What If We Could Prevent It?
By
Sy Mukherjee
November 2, 2017
Health
Could a New Immunotherapy Medical Approach Break the Alzheimer’s Drug Curse?
By
Sy Mukherjee
October 24, 2017
Health
Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock
By
Sy Mukherjee
August 16, 2017
Tech
Do You Really Want to Love Your Medicines?
By
Adam Lashinsky
June 19, 2017
Health
Here’s Why Biogen Is Forking Over $1.25 Billion to a Small Danish Biotech
By
Sy Mukherjee
January 17, 2017
Leadership
This Big Pharma Chief Was Just Named the World’s ‘Best-Performing’ CEO—Again
By
Sy Mukherjee
October 12, 2016
Most Popular
Success
Millionaire Alexis Ohanian walked out of the LSAT 20 minutes in, went to a Waffle House, and decided he was ‘gonna...
By
Preston Fore
Success
Multimillion-dollar restaurant CEO used to splurge on Range Rovers and McLarens—but he’s reining it in now because...
By
Emma Burleigh
Tech
‘Yes, you read that correctly’: Tesla pay committee pitches $1 trillion pact to keep Elon Musk as CEO for long term
By
Nick Lichtenberg